@article{63ebd5b98fa0477bb293094f3327cccc,
title = "Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer",
abstract = "Given the potential interactions between human epidermal growth factor receptor 2 (HER2) signaling and angiogenesis, we investigated the angiopoietin (Ang) 1/Ang2 inhibitor trebananib plus trastuzumab and paclitaxel in HER2-positive breast cancer. Forty women received trebananib (10 or 30 mg/kg) plus trastuzumab and paclitaxel. The combination demonstrated acceptable toxicity and antitumor response in HER2-positive locally recurrent/metastatic breast cancer.",
keywords = "AMG 386, Angiogenesis, Angiopoietin, HER2 positive",
author = "Kaufman, {Peter A.} and Hans Wildiers and Gilles Freyer and Margaret Kemeny and Anthony Gon{\c c}alves and Guy Jerusalem and Alison Stopeck and Nandagopal Vrindavanam and Florence Dalenc and Nuwan Nanayakkara and Benjamin Wu and Pickett, {Cheryl A.}",
note = "Funding Information: The authors thank Jennifer Venzie, PhD, and Miranda Tradewell, PhD (Complete Healthcare Communications LLC, North Wales, PA), for editorial assistance, which was funded by Amgen Inc. This study was funded by Amgen Inc, which was involved in the study design, the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit for publication. Dr. Kaufman has received consulting fees from Amgen Inc and that he holds stocks in Amgen Inc. Funding Information: P.A.K.{\textquoteright}s institution received grants from Amgen Inc ; H.W.{\textquoteright}s institution received speaker{\textquoteright}s fees from Amgen Inc ; G.F. has acted as a consultant for Amgen France; G.J. has received grants from Novartis and Roche , personal fees from Novartis , Roche , Pfizer , Lilly , Celgene , Amgen Inc , BMS , Puma Biotechnology , and Daiichi-Sankyo , nonfinancial support from Novartis, Roche, Pfizer, and Lilly, and his institution received investigator fees from Amgen Inc ; A.S. has received grants and personal fees from Amgen Inc and personal fees from Novartis ; B.W. was an employee of Amgen Inc at the time this study was conducted; and C.A.P. is an employee of and holds stock options in Amgen Inc. The other authors have stated that they have no conflict of interest. Funding Information: P.A.K.'s institution received grants from Amgen Inc; H.W.'s institution received speaker's fees from Amgen Inc; G.F. has acted as a consultant for Amgen France; G.J. has received grants from Novartis and Roche, personal fees from Novartis, Roche, Pfizer, Lilly, Celgene, Amgen Inc, BMS, Puma Biotechnology, and Daiichi-Sankyo, nonfinancial support from Novartis, Roche, Pfizer, and Lilly, and his institution received investigator fees from Amgen Inc; A.S. has received grants and personal fees from Amgen Inc and personal fees from Novartis; B.W. was an employee of Amgen Inc at the time this study was conducted; and C.A.P. is an employee of and holds stock options in Amgen Inc. The other authors have stated that they have no conflict of interest.The authors thank Jennifer Venzie, PhD, and Miranda Tradewell, PhD (Complete Healthcare Communications LLC, North Wales, PA), for editorial assistance, which was funded by Amgen Inc. This study was funded by Amgen Inc, which was involved in the study design, the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit for publication. Dr. Kaufman has received consulting fees from Amgen Inc and that he holds stocks in Amgen Inc. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",
year = "2019",
month = feb,
doi = "10.1016/j.clbc.2018.09.012",
language = "English (US)",
volume = "19",
pages = "47--57",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "1",
}